Abstract
Aim: To determine the association between the use of incretin agents (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) for the treatment of type 2 diabetes mellitus (T2DM) and the risk of any, acute and chronic pancreatitis.
Research design and methods: A population-based cohort study was conducted using data from the UK Clinical Practice Research Datalink (CPRD 2007-2012). A total of 182 428 adult patients with >= 1 non-insulin antidiabetic drug (NIAD) prescription were matched to control subjects without diabetes. Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of pancreatitis in incretin-users (N = 28 370) compared with controls and with other NIAD users. Adjustments were made for lifestyle, disease and drug history. In a sensitivity analysis, a new-user design was used.
Results: Current incretin users had a 1.5-fold increased risk of any pancreatitis compared with NIAD users (adjusted HR 1.47, 95% CI 1.06-2.04). In incident current incretin users the risk of any and acute pancreatitis was increased 2.1-and 2.0-fold compared with NIAD users (adjusted HR 2.12, 95% Cl 1.31-3.43 and adjusted HR 1.96, 95% CI 1.13-3.41), whereas there was no increased risk found for chronic pancreatitis.
Conclusions: Incretin use was associated with an increased risk of any pancreatitis. Moreover, risk of any and acute pancreatitis was higher when applying a new-user design. We were not able to detect an association with chronic pancreatitis, but the number in this subgroup was small.
Original language | English |
---|---|
Pages (from-to) | 401-411 |
Number of pages | 11 |
Journal | Diabetes Obesity & Metabolism |
Volume | 19 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 2017 |
Keywords
- acute pancreatitis
- chronic pancreatitis
- cohort studies
- dipeptidyl peptidase-4 inhibitors
- glucagon-like peptide-1 receptor agonists
- incretin-based therapy
- type 2 diabetes mellitus
- THERAPIES
- CANCER
- DRUGS
- METAANALYSIS
- ASSOCIATION
- RATS
- EXPANSION
- BENEFITS
- UPDATE
- SYSTEM